AMSTERDAM, Nov. 28 /PRNewswire/ -- Oncology focused biopharmaceutical
company Kiadis Pharma announces today that Andrea Velardi, M.D., Professor of
Clinical Immunology at the University of Perugia, Italy and Kiadis Pharma are
continuing their collaboration on ATIR(TM), a product in clinical development
for enabling the use of a mismatched donor in a bone marrow transplantation by
preventing acute Graft versus Host Disease (GvHD) for end stage leukemia
patients. Under the agreement Professor Velardi will continue the development
on the selective depletion of allo-reactive T cells from mismatched donors
using Kiadis Pharma's ATIR(TM). Kiadis Pharma is preparing for a multi-center
pivotal study on ATIR(TM) to start early 2009 and Professor Velardi will
participate in this upcoming study.

"We are very pleased with our continued collaboration with the University
of Perugia and Professor Velardi, who is a leader in the field of mismatched
bone marrow transplantations," says Dr. Manja Bouman, CEO of Kiadis Pharma.
"This collaboration is an important milestone in the development of ATIR(TM)
as a revolutionary approach to provide safe and potentially life-saving
mismatched bone marrow transplantations as a treatment option for end-stage
leukemia patients."

Professor Andrea Velardi says: "So far, we have treated 25 blood cancer
patients who have received bone marrow from mismatched donors, including donor
immune cells that are selectively depleted of cells causing acute Graft versus
Host Disease using the ATIR(TM) process. The results so far are promising and
I am therefore very pleased to continue to work with Kiadis Pharma in this
field."

Kiadis Pharma is an oncology focused pharmaceutical development company
with three products in different phases of clinical development. The company
develops products that offer novel treatment options for terminally ill cancer
patients and address significant unmet medical needs. The key focus indication
for Kiadis Pharma is limitations and complications of bone marrow
transplantation procedures performed in blood cancer patients. Kiadis Pharma
is headquartered in Amsterdam, The Netherlands with facilities in Groningen,
The Netherlands and Montreal, Canada. For more information about Kiadis
Pharma, please visit http://www.kiadis.com.

(Date:12/8/2016)... CA (PRWEB) , ... December 08, 2016 , ... Lajollacooks4u, ... was a banner year for team building events, new program offerings and company expansion. ... it expanded earlier this year to include groups of over 30 people. Ever since, ...

(Date:12/8/2016)... Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...

(Date:11/21/2016)... Lithuania , Nov. 21, 2016 ... and object recognition technologies, today announced that the ... smart cards was submitted for the NIST ... successfully passed all the mandatory steps of the ... evaluation is a continuing test of fingerprint templates ...

(Date:11/15/2016)... Nov. 15, 2016 Synthetic Biologics, Inc. (NYSE ... focused on the gut microbiome, today announced the ... shares of its common stock and warrants to ... a price to the public of $1.00 per ... Biologics from the offering, excluding the proceeds, if ...